
Dyskinesia - Pipeline Insight, 2024
Description
Dyskinesia - Pipeline Insight, 2024
DelveInsight’s, “Dyskinesia - Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Dyskinesia: Overview
Dyskinesia’s are involuntary, erratic, writhing movements of the face, arms, legs or trunk. They are often fluid and dance-like, but they may also cause rapid jerking or slow and extended muscle spasms. They are not a symptom of Parkinson's itself. Rather, they are a complication from some Parkinson's medications. They may be caused by systemic, metabolic, endocrinologic, structural, vascular, infectious or inherited degenerative conditions, or be toxin- or drug-induced. Dyskinesia’s usually begin after a few years of treatment with levodopa and can often be alleviated by adjusting dopaminergic medications. Younger people with PD are thought to develop earlier motor fluctuations and dyskinesia’s in response to levodopa. Dyskinesia’s may be mild and non-bothersome, or they can be severe. Most people with Parkinson’s prefer to be “on” with some dyskinesia’s rather than “off” and unable to move well. However, for some people, dyskinesia’s can be severe enough that they interfere with normal functioning. The most common kind of dyskinesias are “peak dose.” These occur when the concentration of levodopa in the blood is at its highest – usually one to two hours after the persons takes it.
Dyskinesia is a complication of long-term levodopa use in people who have had Parkinson's for several years. Other risk factors include being younger at diagnosis and using higher amounts of levodopa for longer periods of time. Researchers don't know exactly why dyskinesia develops, but they believe a number of brain chemicals, including serotonin, glutamate and dopamine, play a role. Dopamine is particularly important. In Parkinson's, the brain cells that make dopamine are lost, so dopamine levels decrease. Levodopa temporarily restores dopamine, but because the medication has to be taken several times per day, dopamine levels rise and fall. These fluctuating levels, and the continued loss of dopamine-producing brain cells, make it impossible to keep a steady level of dopamine, which contributes to dyskinesia.
With many non-drug-induced dyskinesias, treatment of the underlying condition may be sufficient to eliminate the movements, although temporary treatment may be required to control the movements if they are severe. Drug-induced dyskinesias often resolve when the offending drug is discontinued. A notable exception is tardive dyskinesia, which is caused by exposure to dopamine receptor blocking drugs, the majority of which are antipsychotic agents. Tardive dyskinesias will persist, or may even develop after the causative agent has been stopped and may not spontaneously remit. Another commonly encountered form of drug-induced dyskinesia is seen in patients with Parkinson's disease who are receiving levodopa. Medications which deplete dopamine are most successful in treating choreiform dyskinesias, although anticholinergics, GABAergics, serotonergics, and calcium channel blocking agents have been reportedly beneficial in some cases. Treatment of levodopa-induced dyskinesias requires manipulation of the patient's antiparkinsonian drug regimen.
""Dyskinesia - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dyskinesia pipeline landscape is provided which includes the disease overview and Dyskinesia treatment guidelines. The assessment part of the report embraces, in depth Dyskinesia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dyskinesia R&D. The therapies under development are focused on novel approaches to treat/improve Dyskinesia.
This segment of the Dyskinesia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dyskinesia Emerging Drugs
- JM-010: Contera Pharma
- NLX 112: Neurolixis
- CPL 500036: Celon Pharma
- ETH42: Ethris
Further product details are provided in the report……..
Dyskinesia: Therapeutic Assessment
This segment of the report provides insights about the different Dyskinesia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Dyskinesia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Dyskinesia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dyskinesia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dyskinesia drugs.
Dyskinesia Report Insights
- Dyskinesia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dyskinesia drugs?
- How many Dyskinesia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dyskinesia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dyskinesia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dyskinesia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Contera Pharma
- Ethris
- Neurolixis
- Celon Pharma
- Addex Pharma S.A.
- VistaGen Therapeutics, Inc.
- ReCode Therapeutics
- LuyePharmaGroup
- SOM3366
- Integrative Research Laboratories
- Parion Sciences
- Sumitomo Pharma
- Neurocrine Biosciences
- CYCLE Pharmaceuticals
- JM-010
- CP011
- NLX-112
- CPL 500036
- ETH42
- Dipraglurant
- AV-101
- RCT1100
- ETH44
- LPM3770164
- SOM3366
- Mesdopetam
- Idrevloride
- DSP 9632 P
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Dyskinesia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dyskinesia – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- JM-010: Contera Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- LPM3770164: Luye Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- ETH42: Ethris
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Dyskinesia Key Companies
- Dyskinesia Key Products
- Dyskinesia- Unmet Needs
- Dyskinesia- Market Drivers and Barriers
- Dyskinesia- Future Perspectives and Conclusion
- Dyskinesia Analyst Views
- Dyskinesia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.